Squarepoint Ops LLC purchased a new position in shares of Rapport Therapeutics (NASDAQ:RAPP – Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 16,345 shares of the company’s stock, valued at approximately $380,000.
A number of other institutional investors have also modified their holdings of RAPP. Sandia Investment Management LP acquired a new stake in Rapport Therapeutics during the second quarter worth approximately $116,000. ARCH Venture Management LLC acquired a new stake in shares of Rapport Therapeutics during the 2nd quarter worth $86,730,000. Davidson Kempner Capital Management LP purchased a new position in shares of Rapport Therapeutics in the 2nd quarter worth $229,000. Sofinnova Investments Inc. acquired a new stake in Rapport Therapeutics during the second quarter worth about $45,393,000. Finally, Johnson & Johnson purchased a new position in Rapport Therapeutics in the second quarter valued at approximately $58,105,000.
Rapport Therapeutics Stock Up 4.7 %
Rapport Therapeutics stock opened at $20.41 on Friday. Rapport Therapeutics has a 12-month low of $16.55 and a 12-month high of $28.08. The company has a 50 day moving average of $20.35.
Wall Street Analyst Weigh In
RAPP has been the subject of several recent research reports. Jefferies Financial Group initiated coverage on Rapport Therapeutics in a report on Tuesday, July 2nd. They issued a “buy” rating and a $35.00 price target for the company. TD Cowen assumed coverage on shares of Rapport Therapeutics in a research report on Tuesday, July 2nd. They set a “buy” rating for the company. Finally, Stifel Nicolaus began coverage on shares of Rapport Therapeutics in a research note on Tuesday, July 2nd. They set a “buy” rating and a $35.00 target price for the company.
Rapport Therapeutics Profile
Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.
Further Reading
- Five stocks we like better than Rapport Therapeutics
- Trading Stocks: RSI and Why it’s Useful
- MercadoLibre Targets Double-Digit Upside with Argentina Boom
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Domino’s Pizza Stock Delivers: A Hot Buy for Growth Investors
- Investing in Travel Stocks Benefits
- 3 Small-Cap Stocks Ready to Deliver Significant Growth
Receive News & Ratings for Rapport Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rapport Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.